Navigation Links
Lexicon Completes Phase 2 Study Of LX1033 In IBS-d
Date:12/3/2013

g statements," including statements relating to Lexicon's clinical development of LX1033, characterizations of the results of and projected timing of clinical trials of LX1033, and the potential therapeutic and commercial potential of LX1033.  The press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX1033 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2012, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon to Provide First Quarter 2012 Financial Results
2. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
3. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
4. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
5. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
6. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
7. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
8. Lexicon to Provide Second Quarter 2012 Financial Results
9. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
10. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
11. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... -- Commonwealth Cornerstone Group (CCG) today announced the completion of an ... help fund the expansion and consolidation of healthcare services provided ... . PHN is the largest federally qualified ... is the largest employer in Sharon,s ... Currently, PHN Sharon offers scattered services out of ...
(Date:12/24/2014)... , Dec. 24, 2014 Soligenix, ... late-stage biopharmaceutical company developing products that address unmet ... and biodefense, announced today that on December 24, ... offering. The Company raised approximately $2.3 ... intends to use the net proceeds from the ...
(Date:12/24/2014)... Mich. , Dec. 24, 2014  Diplomat Pharmacy, ... independent specialty pharmacy, is proud to announce Jennifer ... quality at Diplomat, will take office as the president ... The formal induction ceremony will take place Feb. 28, ... will be held at the Renaissance Center in ...
Breaking Medicine Technology:Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3
... - Positive data on subcutaneous administration show potential ... CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Millennium,Pharmaceuticals, Inc. ... the market-leading therapy for patients with,multiple myeloma (MM) ... data include results from a Phase II trial ...
... CHICAGO, June 04, 2007 /PRNewswire/ -- GlaxoSmithKline ... of pazopanib in,advanced or metastatic renal cell ... (STS). These trials were presented at the,43rd ... Clinical Oncology,(ASCO) in Chicago. The results observed ...
Cached Medicine Technology:New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 2New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 3New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 4New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 5New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 6New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 7GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 2GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 3GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 4GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 5GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 6GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 7
(Date:12/26/2014)... (PRWEB) December 26, 2014 India Network ... insurance in the USA, announced today a new version ... members in choosing the right plan for their visiting ... complexity out of the selection process when choosing an ... age group with only a few clicks. Many elderly ...
(Date:12/25/2014)... This is a professional and in-depth study on ... a focus on the Chinese market. The report provides ... manufacturers and is a valuable source of guidance and ... This report provides a basic overview of the industry ... part, the report presents the company profile, product specifications, ...
(Date:12/25/2014)... three months the trends for evening dresses shift ... one of the hottest styles in the next few months.” ... releases 26 A-line sweetheart evening dresses, and announces the availability ... are trying our best to help a lady to show ... affordable prices, we provide discounted delivery costs to our customers ...
(Date:12/25/2014)... BambooFlooringChina.com sells many bamboo products and the business is ... company announces big discounts on its bamboo mats , ... is the world’s leader in bamboo flooring. According to ... 20, 2015. , The bamboo mats are made from ... All the bamboo strips for the mats are boiled ...
(Date:12/25/2014)... Dec. 25, 2014 (HealthDay News) -- The risk of ... holidays, so you need to be extra cautious, an ... we see a significant increase in patients coming in ... the Suffolk County Volunteer Firefighters Burn Center of Stony ... should be full of joy, but if not careful, ...
Breaking Medicine News(10 mins):Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Don't Let Burns Mar Your Holidays 2
... Bill Includes Three Provisions That Protect Patient Access ... The U.S. Senate and,House of Representatives have voted ... 6331, the Medicare Improvements for Patients and Providers ... executive vice president and,CEO of the National Community ...
... executives within the accounting and finance, advertising/marketing, ... human resources, legal, medical device/pharmaceutical, military transition ... industries. With offices nationwide and its expansion ... for Fortune 100+ companies, as well as ...
... company who pioneered web-based vendor access services for healthcare facilities, ... representatives operate more efficiently and increase facility safety. , ... ... 2008 -- VendorClear™, the company who pioneered web-based vendor access ...
... Friday, July 18, 2008 the young,scientists at Happy Faces ... partaking in Cornell University,s Lost Lady Bug Project. They ... and releasing,ladybugs. Memorial Field is located off Valley Parkway ... River. Their findings will be,sent to Cornell,s Entomology department ...
... 15 , WHAT: SheKnows ( http://www.SheKnows.com ) partners with DKMS ... largest bone marrow donor ... ( http://www.helpgiovanniguglielmo.org ) to promote awareness of ... to International Bone Marrow ...
... Global Pain Management Franchise, MADISON, N.J., July ... (NYSE: WYE ), announced today that it ... over-the-counter,heat wrap, from Procter & Gamble (NYSE: ... the next few months., ThermaCare fits Wyeth ...
Cached Medicine News:Health News:Lucas Group Celebrates Its 38th Anniversary 2Health News:VendorClear™ Introduces Revolutionary Products for Healthcare Facilities and Vendor Representatives 2Health News:Lakewood Childcare Participates in Ladybug Hunt 2Health News:SheKnows to Launch Bone Marrow Awareness Campaign and Add 50,000 New Donors 2Health News:Wyeth Consumer Healthcare Signs Agreement to Purchase ThermaCare from Procter & Gamble 2Health News:Wyeth Consumer Healthcare Signs Agreement to Purchase ThermaCare from Procter & Gamble 3Health News:Wyeth Consumer Healthcare Signs Agreement to Purchase ThermaCare from Procter & Gamble 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: